Toronto, Ontario –October 31, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that a recent peer-reviewed paper entitled, “Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy”, presenting research on Theralase licensed Osmium PDCs, has been independently reviewed by Dr. Edith C. Glazer in her recent paper entitled, “Panchromatic Osmium Complexes for Photodynamic Therapy: Solutions to Existing Problems and New Questions”. Edith C. Glazer, Ph.D., Associate Professor, Department of Biological Chemistry, University of Kentucky, Lexington, Kentucky provided an independent review of “Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy” where she states that, “The validation of Osmium coordination complexes as photosensitizers for PDT, with very promising in vivo results, demonstrate radical improvements in survival following irradiation … Read More

Toronto, Ontario –October 30, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research will be presented at the 2018 International Society for Optical Engineering (“SPIE”) Photonics West to be held in San Francisco, California from January 27th to February 1st, 2018. SPIE Photonics West is the world’s largest photonics technologies event, consisting of three conferences and two world-class exhibitions. Every year over 20,000 participants attend to learn more about the latest research and technology in: translational biophotonics, global healthcare, understanding the brain, new lasers for manufacturing, applications of 3D technologies, photonics-based consumer products and other related subject matters. The “Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXVII” chairing committee have … Read More

Toronto, Ontario – September 25, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, when activated by X-rays, has been demonstrated preclinically, to be effective in the destruction of human GlioBlastoma Multiforme (“GBM”) cancer cells, a deadly form of brain cancer. According to the American Brain Tumor Association: “GBM are tumors that arise from astrocytes—the star-shaped cells that make up the “glue-like,” or supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly, being supported by a large network of blood vessels.” “Nearly 80,000 new cases of primary brain tumors are expected to be diagnosed in the US this year, with approximately 32% of brain and central … Read More

Toronto, Ontario – September 19, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human pharyngeal carcinoma cell line, FaDu. In 2016, according to the American Society of Clinical Oncology (“ASCO”), an estimated 49,670 adults (35,720 men and 13,950 women) in the United States will be diagnosed with oral and oropharyngeal cancer. Rates of these cancers are more than twice as high in men, as in women. Cancer of the oral cavity is the ninth most common cancer among men. The average age of diagnosis is 62. The overall 5-year survival rate for people with oral or oropharyngeal cancer is 64%. It is estimated … Read More

Toronto, Ontario – September 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated 24 months long term stability of it lead anti-cancer PDC, TLD-1433. Stability studies are an essential component of pharmaceutical development, allowing evaluation of a drug’s stability under the influence of a variety of environmental factors such as: temperature, humidity and light. Data from these studies enable recommended storage conditions, retest intervals and shelf lives to be established. Demonstrating long term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life. TLD-1433, in the most recent testing report, demonstrated that its purity has … Read More

Toronto, Ontario – September 12, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated increased efficacy with its latest, patented, licensed, anti-cancer drug, TLD-1633, when compared to its lead anti-cancer drug, TLD-1433. The latest PDC, known as TLD-1633, has recently been shown to be approximately 15% more effective than TLD-1433 in the destruction of a human Glioblastoma Multiforme (“GBM”) cell line (U87), a deadly form of brain cancer. In preclinical research, TLD-1633 has also demonstrated a lower dark toxicity, supporting an even higher safety profile than TLD-1433. TLD-1633 Photo Dynamic Therapy (“PDT”) when activated by green laser light (530 nm, 90 J/cm2) and dark toxicity (no laser light) compared to TLD-1433 in U87 GBM cells. Pavel … Read More

Toronto, Ontario – September 5, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human cervical carcinoma cell line, ME180. The American Cancer Society’s estimates for cervical cancer in the United States for 2017 are: About 12,820 new cases of invasive cervical cancer will be diagnosed About 4,210 women will die from cervical cancer Cervical cancer was once one of the most common causes of cancer death for American women, but over the last 40 years, the cervical cancer death rate has gone down by more than 50%, due to the increased use of the Pap test. In research conducted by Pavel Kaspler, Ph.D., … Read More

Toronto, Ontario – August 29, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the six-month period ended June 30, 2017, total revenue increased to $1,016,734 from $893,138 for the same period in 2016, a 14% increase. In Canada, revenue increased 55% to $769,840 from $497,378. In the US, revenue decreased 33% to $211,453 from $316,756 and international revenue decreased 55% to $35,441 from $79,004. The increase in Canadian revenue in 2017 and the corresponding decrease in US and international revenue is attributable to the Company systematically building its sales and marketing teams in the Canadian market, the learning curves associated with training and developing a new sales force in the US and the ramp-up strategy of successfully … Read More

Toronto, Ontario – August 22, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, and associated family of compounds, have been independently verified and validated in a peer-reviewed publication. A detailed computational investigation (“Study”) by Marta Alberto and coworkers entitled “Theoretical Exploration of Type I/Type II Dual Photoreactivity of Promising Ru(II) Dyads for PDT Approach”, appearing in the peer-reviewed American Chemical Society (“ACS”) journal Inorganic Chemistry, has independently verified and validated the unique photophysical properties of Theralase’s lead Photo Dynamic Compound (“PDC”), TLD-1433 and associated family of compounds. Click here to view The Study The Study details how Dr. Sherri McFarland (“McFarland”) has pioneered the use of specialized excited states for dual-mode Type … Read More

Toronto, Ontario – August 8, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that its lead compound, TLD-1433, combined with transferrin to form Rutherrin®, has been demonstrated to localize to and destroy various forms of lung cancer, when laser light activated, in an in-vitro and in an in-vivo animal model. Lung cancer is the leading cancer killer in both men and women. Out of all lung cancers, Non-Small Cell Lung Cancer (“NSCLC”) accounts for more than 85% of all lung cancers. In 2016, an estimated 20,800 Canadians died from lung cancer, representing 26% of all cancer deaths, while an estimated 158,080 Americans died, representing 27% of all cancer deaths. Current standard treatment for NSCLC is surgery followed … Read More